Abstract
The aim of this study was to evaluate the abuse potential of dasotraline, a novel dopamine and norepinephrine reuptake inhibitor with slow absorption (tmax, 10-12h) and elimination (t1/2=47-77 h) that is in development for the treatment of attention deficit hyperactivity disorder (ADHD). Recreational stimulant users (N=48) who had specific experience with cocaine, and who were able to distinguish methylphenidate (60 mg) versus placebo in a qualification session, were randomized, in a 6-period, double-blind, crossover design, to receive single doses of dasotraline 8 mg, 16 mg, and 36 mg, methylphenidate (MPH) 40 mg and 80 mg, and placebo. The primary endpoint was the Drug Liking Visual Analog Scale (VAS) score at the time of peak effect (Emax). There were no significant differences between the 3 doses of dasotraline and placebo on the drug liking VAS at Emax, and on most secondary endpoints. Both doses of MPH had significantly higher VAS-drug liking scores at Emax relative to both placebo (P<0.001 for all comparisons) and dasotraline 8 mg (P<0.001), 16 mg (P<0.001) and 36 mg (P<0.01). The increase in heart rate for MPH and dasotraline 36 mg showed a time-course that closely matched subject-rated measures such as Any Effects VAS....Continue Reading
References
Dec 1, 1991·British Journal of Addiction·M Farré, J Camí
Jun 1, 1995·Archives of General Psychiatry·N D VolkowR Hitzemann
Dec 10, 1997·Clinical Pharmacokinetics·D I QuinnR O Day
Apr 11, 2000·Journal of Psychopharmacology·D R Jasinski
Apr 28, 2001·Pharmacology, Biochemistry, and Behavior·S H KollinsC R Rush
Jul 4, 2002·Drug and Alcohol Dependence·S H HeilD E Faries
May 22, 2003·Drug and Alcohol Dependence·Robert L Balster, George E Bigelow
May 22, 2003·Drug and Alcohol Dependence·Roland R GriffithsNancy A Ator
Nov 5, 2003·The American Journal of Psychiatry·Nora D Volkow, James M Swanson
Nov 20, 2003·Neuroscience and Biobehavioral Reviews·J M Swanson, N D Volkow
Feb 25, 2005·Experimental and Clinical Psychopharmacology·William W StoopsCraig R Rush
Mar 24, 2006·Drug and Alcohol Dependence·Shelley McColl, Edward M Sellers
Oct 27, 2007·Journal of Clinical Pharmacology·Dolly A ParasrampuriaEdward M Sellers
Jan 5, 2008·Journal of the American Academy of Child and Adolescent Psychiatry·Timothy E WilensSteven Fusillo
Mar 11, 2008·Drug and Alcohol Dependence·Donald R JasinskiAlbert J Allen
Apr 3, 2008·The American Journal of Psychiatry·Salvatore MannuzzaFrancisco X Castellanos
Jan 7, 2010·The Journal of Clinical Psychiatry·Stephen V Faraone, Stephen J Glatt
Aug 20, 2010·Journal of Pain & Palliative Care Pharmacotherapy·UNKNOWN U.S. Food And Drug Administration
Dec 24, 2011·The American Journal of Psychiatry·Kelly PosnerJ John Mann
Feb 9, 2012·Postgraduate Medicine·Thomas J SpencerStephen V Faraone
Oct 5, 2013·Addictive Behaviors·Søren DalsgaardPer Hove Thomsen
Oct 9, 2014·Postgraduate Medicine·David B Clemow, Daniel J Walker
May 8, 2015·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Kenneth S KoblanAntony Loebel
Citations
Jan 30, 2019·Journal of Child and Adolescent Psychopharmacology·Robert L FindlingAntony Loebel
Mar 16, 2019·Expert Review of Neurotherapeutics·Pankhuree Vandana, Eugene Arnold
May 20, 2020·CNS Spectrums·Carlos M GriloAntony Loebel
Aug 20, 2020·Psychopharmacology·Robert LewSeth C Hopkins
Jun 15, 2019·CNS Spectrums·Leslie Citrome
Mar 17, 2021·International Clinical Psychopharmacology·Lenard A AdlerAntony Loebel
Jul 29, 2021·Journal of Psychopharmacology·David J Heal, Sharon L Smith
Jul 22, 2017·Journal of Medicinal Chemistry·Murugaiah A M Subbaiah